Background Testing with THC
Firstly, there is solid reasoning behind the hypothesis that cannabis and its constituent cannabinoids like CBD and THC could be used to treat the symptoms of COVID-19. Key to the hypothesis is the fact that the deaths associated with the virus are thought to occur in large part due to the body’s own immune response being overly reactive. When the body has this overreacting immune system, such as in severe cases of COVID-19, the resulting inflammation can harm the body’s own tissues, such as lung tissue where respiratory failure can occur.
Research has shown that THC and CBD can alter the body’s inflammatory response and help avert inflammatory damage being done to tissues and organs. In fact, cannabinoids regulate the exact same inflammatory proteins responsible for some of the damage occurring in COVID-19 cases. However, there is a suggestion that cannabinoids can reduce the immune response too much, and smoking of any kind is a possible risk factor for worsening symptoms, so, at this point, patients must exercise caution.
Before the leap is made to promote or reject cannabinoids as a treatment for COVID-19, the medicines must be tested thoroughly for safety and effectiveness, which is where clinical trials come in.